Comparison Overview

MENARINI Group

VS

Alkem Laboratories Ltd.

MENARINI Group

Via dei Sette Santi 1/3, Firenze, Italy, IT, 50131
Last Update: 2025-12-09
Between 750 and 799

The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 10,572
Subsidiaries: 26
12-month incidents
0
Known data breaches
0
Attack type number
0

Alkem Laboratories Ltd.

Lower Parel, Alkem House , Mumbai, IN, 400013
Last Update: 2025-12-09
Between 750 and 799

A single idea, which sprouts from a human mind, contains the potential to create marvels that can influence generations. It can redefine rules, it can transform the world. Back in the year 1973, a team of individuals came with such an idea – The idea called Alkem. It was highly potent and resilient, like a spark that could ignite a thousand more ideas. And it did! Looking back at our 4 decade, illustrious journey, that one small idea has Not only triggered us to become one of India’s largest generic and specialty pharmaceutical company but also, create a foothold in over 50 countries 32% of our revenue is generated via offshore sales. As well as we have consistently been ranked amongst the top ten pharmaceutical companies in India. Our portfolio includes illustrious brands like Clavam, Pan, Pan-D and Taxim-O, which feature amongst top 50 pharmaceutical brands in India. For over a decade, our dominance in anti-infective segment has remained unchallenged. We have 21 manufacturing facilities at multiple locations in India and the United States of America. Our upper-crest facilities are inspected and audited as per cGMP guidelines as laid down by leading regulatory authorities such as USFDA, MHRA - UK, SAHPRA-South Africa, TGA - Australia, ANVISA - Brazil, WHO - Geneva, TPD - Health Canada, PPB - Kenya, NDA - Uganda, MOH - Sudan, INVIMA - Colombia, TFDA - Tanzania, Zimbabwe, BfArM-Germany & Other Africa, Asian & CIS Countries. Another feather in our cap was added on December 23rd, 2015, when, Alkem completed it's Initial Public Offering (IPO) and was listed on the Bombay Stock Exchange Limited and the National Stock Exchange of India Limited. Although passion is the fuel that keeps ideas alive, innovation is the catalyst that gives it flight! With over 500 scientists working in 5 global R&D centers, we are empowering innovations that align with our philosophy of ‘Extended Lifecare Beyond Boundaries’.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 15,251
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/alkem-laboratories-ltd.jpeg
Alkem Laboratories Ltd.
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
MENARINI Group
100%
Compliance Rate
0/4 Standards Verified
Alkem Laboratories Ltd.
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for MENARINI Group in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for Alkem Laboratories Ltd. in 2025.

Incident History — MENARINI Group (X = Date, Y = Severity)

MENARINI Group cyber incidents detection timeline including parent company and subsidiaries

Incident History — Alkem Laboratories Ltd. (X = Date, Y = Severity)

Alkem Laboratories Ltd. cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/menarini.jpeg
MENARINI Group
Incidents

No Incident

https://images.rankiteo.com/companyimages/alkem-laboratories-ltd.jpeg
Alkem Laboratories Ltd.
Incidents

No Incident

FAQ

MENARINI Group company demonstrates a stronger AI Cybersecurity Score compared to Alkem Laboratories Ltd. company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

Historically, Alkem Laboratories Ltd. company has disclosed a higher number of cyber incidents compared to MENARINI Group company.

In the current year, Alkem Laboratories Ltd. company and MENARINI Group company have not reported any cyber incidents.

Neither Alkem Laboratories Ltd. company nor MENARINI Group company has reported experiencing a ransomware attack publicly.

Neither Alkem Laboratories Ltd. company nor MENARINI Group company has reported experiencing a data breach publicly.

Neither Alkem Laboratories Ltd. company nor MENARINI Group company has reported experiencing targeted cyberattacks publicly.

Neither MENARINI Group company nor Alkem Laboratories Ltd. company has reported experiencing or disclosing vulnerabilities publicly.

Neither MENARINI Group nor Alkem Laboratories Ltd. holds any compliance certifications.

Neither company holds any compliance certifications.

MENARINI Group company has more subsidiaries worldwide compared to Alkem Laboratories Ltd. company.

Alkem Laboratories Ltd. company employs more people globally than MENARINI Group company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither MENARINI Group nor Alkem Laboratories Ltd. holds SOC 2 Type 1 certification.

Neither MENARINI Group nor Alkem Laboratories Ltd. holds SOC 2 Type 2 certification.

Neither MENARINI Group nor Alkem Laboratories Ltd. holds ISO 27001 certification.

Neither MENARINI Group nor Alkem Laboratories Ltd. holds PCI DSS certification.

Neither MENARINI Group nor Alkem Laboratories Ltd. holds HIPAA certification.

Neither MENARINI Group nor Alkem Laboratories Ltd. holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

NXLog Agent before 6.11 can load a file specified by the OPENSSL_CONF environment variable.

Risk Information
cvss3
Base: 8.1
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:H/I:H/A:H
Description

uriparser through 0.9.9 allows unbounded recursion and stack consumption, as demonstrated by ParseMustBeSegmentNzNc with large input containing many commas.

Risk Information
cvss3
Base: 2.9
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:U/C:N/I:N/A:L
Description

A vulnerability was detected in Mayan EDMS up to 4.10.1. The affected element is an unknown function of the file /authentication/. The manipulation results in cross site scripting. The attack may be performed from remote. The exploit is now public and may be used. Upgrading to version 4.10.2 is sufficient to fix this issue. You should upgrade the affected component. The vendor confirms that this is "[f]ixed in version 4.10.2". Furthermore, that "[b]ackports for older versions in process and will be out as soon as their respective CI pipelines complete."

Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:P/A:N
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:L/A:N
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

MJML through 4.18.0 allows mj-include directory traversal to test file existence and (in the type="css" case) read files. NOTE: this issue exists because of an incomplete fix for CVE-2020-12827.

Risk Information
cvss3
Base: 4.5
Severity: HIGH
CVSS:3.1/AV:L/AC:H/PR:N/UI:N/S:C/C:L/I:N/A:L
Description

A half-blind Server Side Request Forgery (SSRF) vulnerability exists in kube-controller-manager when using the in-tree Portworx StorageClass. This vulnerability allows authorized users to leak arbitrary information from unprotected endpoints in the control plane’s host network (including link-local or loopback services).

Risk Information
cvss3
Base: 5.8
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:H/UI:N/S:C/C:H/I:N/A:N